Clinical Trial Update: A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety and efficacy of COM701 in relapsed platinum-sensitive ovarian cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• COM701

Snippet

Sponsor: Compugen Ltd | Conditions: Ovarian Cancer, Ovarian Cancer Recurrent | Phase 1, Phase 2 | Status: RECRUITING